These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 32730586)

  • 1. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
    Bartlett NL; Herrera AF; Domingo-Domenech E; Mehta A; Forero-Torres A; Garcia-Sanz R; Armand P; Devata S; Izquierdo AR; Lossos IS; Reeder C; Sher T; Chen R; Schwarz SE; Alland L; Strassz A; Prier K; Choe-Juliak C; Ansell SM
    Blood; 2020 Nov; 136(21):2401-2409. PubMed ID: 32730586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
    Rothe A; Sasse S; Topp MS; Eichenauer DA; Hummel H; Reiners KS; Dietlein M; Kuhnert G; Kessler J; Buerkle C; Ravic M; Knackmuss S; Marschner JP; Pogge von Strandmann E; Borchmann P; Engert A
    Blood; 2015 Jun; 125(26):4024-31. PubMed ID: 25887777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.
    Borchmann P; Schnell R; Fuss I; Manzke O; Davis T; Lewis LD; Behnke D; Wickenhauser C; Schiller P; Diehl V; Engert A
    Blood; 2002 Nov; 100(9):3101-7. PubMed ID: 12384405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
    Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
    MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30
    Kerbauy LN; Marin ND; Kaplan M; Banerjee PP; Berrien-Elliott MM; Becker-Hapak M; Basar R; Foster M; Garcia Melo L; Neal CC; McClain E; Daher M; Nunez Cortes AK; Desai S; Inng Lim FW; Mendt MC; Schappe T; Li L; Shaim H; Shanley M; Ensley EL; Uprety N; Wong P; Liu E; Ang SO; Cai R; Nandivada V; Mohanty V; Miao Q; Shen Y; Baran N; Fowlkes NW; Chen K; Muniz-Feliciano L; Champlin RE; Nieto YL; Koch J; Treder M; Fischer W; Okamoto OK; Shpall EJ; Fehniger TA; Rezvani K
    Clin Cancer Res; 2021 Jul; 27(13):3744-3756. PubMed ID: 33986022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.
    Sasse S; Bröckelmann PJ; Momotow J; Plütschow A; Hüttmann A; Basara N; Koenecke C; Martin S; Bentz M; Grosse-Thie C; Thorspecken S; de Wit M; Kobe C; Dietlein M; Tresckow BV; Fuchs M; Borchmann P; Engert A
    Leuk Lymphoma; 2022 Aug; 63(8):1871-1878. PubMed ID: 35848865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
    Ramos CA; Grover NS; Beaven AW; Lulla PD; Wu MF; Ivanova A; Wang T; Shea TC; Rooney CM; Dittus C; Park SI; Gee AP; Eldridge PW; McKay KL; Mehta B; Cheng CJ; Buchanan FB; Grilley BJ; Morrison K; Brenner MK; Serody JS; Dotti G; Heslop HE; Savoldo B
    J Clin Oncol; 2020 Nov; 38(32):3794-3804. PubMed ID: 32701411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Aug; 8():96. PubMed ID: 26231785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
    Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
    MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted immunotherapy in Hodgkin lymphoma.
    Hutchings M
    Blood; 2015 Jun; 125(26):3967-8. PubMed ID: 26113529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease.
    Hartmann F; Renner C; Jung W; Pfreundschuh M
    Leuk Lymphoma; 1998 Oct; 31(3-4):385-92. PubMed ID: 9869203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
    Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
    Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
    Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
    Renner C; Hartmann F; Jung W; Deisting C; Juwana M; Pfreundschuh M
    Cancer Immunol Immunother; 2000 Jun; 49(3):173-80. PubMed ID: 10881697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab for the treatment of Hodgkin Lymphoma.
    Al Hadidi SA; Lee HJ
    Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
    Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
    Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.